in United States, Europe and Asia. Clinical trials Casa Sollievo della Sofferenza conducts clinical trials in collaboration with pharmaceutical companies. At present, there are more than 200 clinical trials in progress in the areas like amyotrophic lateral sclerosis, multiple sclerosis, glioblastoma and Huntington's disease. There are 171 published articles from Casa Sollievo della Sofferenza that have involved Clinical Trials of Phase I or II and 25 published articles that have involved successful Phase III Clinical Trials so far. Non-profit clinical trials IRCCS Casa Sollievo della Sofferenza is also the first in the world to run a not-for-profit Phase I Clinical Trial on transplantation of neural stem cells for the patients who are suffering from Amyotrophic Lateral Sclerosis. Institute for Stem-Cell Biology, Regenerative Medicine and Innovative Therapies at Casa Sollievo della Sofferenza will also run non-profit clinical trials against sla, multiple sclerosis and glioblastoma. ISBReMIT (Institute for Stem-cell Biology, Regenerative Medicine and Innovative Therapies) Casa Sollievo della Sofferenza has established ISBReMIT, a brand-new research centre for stem cells and regenerative medicine, with a grant of 14.4 Million Euro from Italian Ministry of Education, Universities and Research. ISBReMIT is the first factory of GMP neural stem cells in Europe and will produce the pharmaceutical grade cells which will be used in clinical trials. This research centre also has an area dedicated to start-up companies for the commercialisation of research. This new building is built between the John Paul II clinic and the hospital building of Casa Sollievo della Sofferenza. It has been structured to produce cellular therapies, gene therapies and prostheses made up of biomaterials, and will run non-profit clinical trials against sla, multiple sclerosis and glioblastoma. Cancer Stem Cell Unit at ISBReMIT This unit of Casa Sollievo della Sofferenza is developing selective biopharmaceuticals. It is working in collaboration with two innovative startups StemGen, Italy and HyperStem SA, Switzerland to revolutionize technology of cancer stem cells in experimentation on patients. Medical Genetics Unit Major activities of this research unit include-discovery of disease related genes, study of genomic signatures in disease pathology, analysis of deregulated pathyways in complex pathologies and functional studies of mutations in genes associated with tumour and other complex diseases. Dr. Giuseppe Merla, a scientist from IRCCS Casa Sollievo della Sofferenza Medical Genetics Unit led the discovery of a novel rare genetic syndrome- IDDCA (intellectual development disorder with cardiac arrhythmia) along with collaborators from America, the Netherlands, Brazil and Switzerland.